Search Patents
  • Publication number: 20160339097
    Abstract: Disclosed herein are embodiments of a method for collecting, extracting or eluting proteins and antigens from cells infected with coronavirus. The coronavirus may be a porcine coronavirus, such as porcine epidemic diarrhea virus (PEDV) or porcine delta coronavirus (PDCoV). Also disclosed are embodiments of a composition comprising the coronavirus proteins and antigens, and embodiments of a method of using such a composition. Applications for the composition include, but are not limited to, use in the preparation of antibodies against the proteins and antigens, use as reference markers for coronavirus proteins, and/or use in an immunogenic composition, such as in a vaccine composition.
    Type: Application
    Filed: August 4, 2016
    Publication date: November 24, 2016
    Applicant: MJ Biologics, Inc.
    Inventor: Byoung-Kwan Kim
  • Publication number: 20190202868
    Abstract: Disclosed herein are embodiments of a method for collecting, extracting or eluting proteins and antigens from cells infected with coronavirus. The coronavirus may be a porcine coronavirus, such as porcine epidemic diarrhea virus (PEDV) or porcine delta coronavirus (PDCoV). Also disclosed are embodiments of a composition comprising the coronavirus proteins and antigens, and embodiments of a method of using such a composition. Applications for the composition include, but are not limited to, use in the preparation of antibodies against the proteins and antigens, use as reference markers for coronavirus proteins, and/or use in an immunogenic composition, such as in a vaccine composition.
    Type: Application
    Filed: March 15, 2019
    Publication date: July 4, 2019
    Applicant: Phibro Animal Health Corporation
    Inventor: Byoung-Kwan Kim
  • Patent number: 10280199
    Abstract: Disclosed herein are embodiments of a method for collecting, extracting or eluting proteins and antigens from cells infected with coronavirus. The coronavirus may be a porcine coronavirus, such as porcine epidemic diarrhea virus (PEDV) or porcine delta coronavirus (PDCoV). Also disclosed are embodiments of a composition comprising the coronavirus proteins and antigens, and embodiments of a method of using such a composition. Applications for the composition include, but are not limited to, use in the preparation of antibodies against the proteins and antigens, use as reference markers for coronavirus proteins, and/or use in an immunogenic composition, such as in a vaccine composition.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: May 7, 2019
    Assignee: Phibro Animal Health Corporation
    Inventor: Byoung-Kwan Kim
  • Publication number: 20060286124
    Abstract: The present disclosure relates to compositions and methods for treating or preventing coronavirus infections. For example, compositions are provided that comprise a coronavirus S protein or N protein, fragment, or variant thereof, capable of eliciting a protective humoral and/or cell-mediated immune response, which compositions are useful for treating or preventing infection by coronavirus, such as the causative agent of SARS. Also, coronavirus S protein and N protein immunogen compositions are provided that include an adjuvant, such as Proteosome or Protollin, which may be used for treating or preventing infection caused by a coronavirus, such as a SARS coronavirus.
    Type: Application
    Filed: June 30, 2005
    Publication date: December 21, 2006
    Applicant: ID Biomedical Corporation of Quebec
    Inventors: David Burt, Mark Reddish, Mary Hu, George Lowell, David Jones
  • Publication number: 20050276818
    Abstract: The present invention relates to novel methods for identifying antiviral agents which selectively interfere with viral proteins that cause the unique infectivity activity of the SARS-coronavirus in comparison to other non-SARS strains of coronavirus. In particular, the present invention relates to screening assays that identify agents which selectively inhibit cyclic-AMP dependent protein kinase activity of the SARS-coronavirus ORF3. The present invention also relates to screening assays that identify agents which selectively inhibit the interaction between SARS-coronavirus cyclic-AMP dependent protein kinase and a calcium dependent targeting molecule. Therefore the agents identified using the assays of the invention may have utility as antiviral agents. The present invention also relates to treatments for sever acute respiratory syndrome caused by a coronavirus, and particularly to treatments that affect the infectivity activity of the SARS-coronavirus.
    Type: Application
    Filed: May 17, 2005
    Publication date: December 15, 2005
    Inventors: Adam Godzik, Sergey Sikora
  • Patent number: 7504205
    Abstract: The present invention relates to novel methods for identifying antiviral agents which selectively interfere with viral proteins that cause the unique infectivity activity of the SARS-coronavirus in comparison to other non-SARS strains of coronavirus. In particular, the present invention relates to screening assays that identify agents which selectively inhibit cyclic-AMP dependent protein kinase activity of the SARS-coronavirus ORF3. The present invention also relates to screening assays that identify agents which selectively inhibit the interaction between SARS-coronavirus cyclic-AMP dependent protein kinase and a calcium dependent targeting molecule. Therefore the agents identified using the assays of the invention may have utility as antiviral agents. The present invention also relates to treatments for sever acute respiratory syndrome caused by a coronavirus, and particularly to treatments that affect the infectivity activity of the SARS-coronavirus.
    Type: Grant
    Filed: May 17, 2005
    Date of Patent: March 17, 2009
    Assignee: The Burnham Institute
    Inventors: Adam Godzik, Sergey Sikora
  • Patent number: 4567042
    Abstract: An efficacious parenterally administered inactivated canine coronavirus vaccine which provides systemic, humoral protection and also protection of the intestinal tract in dogs from infection by virulent canine coronavirus is produced. A method for propagation of the canine coronavirus and its attenuation and a method of evaluating the effectiveness of a canine coronavirus vaccine in canines is also disclosed.
    Type: Grant
    Filed: June 7, 1984
    Date of Patent: January 28, 1986
    Assignee: American Home Products Corporation
    Inventors: William M. Acree, Bobby Edwards, John W. Black
  • Publication number: 20090081780
    Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (e.g., Quebec and LY138) and human coronavirus strain OC43.
    Type: Application
    Filed: September 26, 2008
    Publication date: March 26, 2009
    Applicant: The Royal Veterinary College
    Inventors: John Brownlie, Victoria Jane Chalker, Kerstin Erles
  • Publication number: 20200061185
    Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.
    Type: Application
    Filed: October 25, 2017
    Publication date: February 27, 2020
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, The Scripps Research Institute, Trustees of Dartmouth College
    Inventors: Barney Graham, Jason McLellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
  • Publication number: 20100304363
    Abstract: Disclosed herein are peptide compounds and the application thereof to the detection and inhibition of SARS coronavirus. Composed of dipeptides, the compounds for detecting and inhibiting SARS coronavirus can be readily synthesized and produced at low cost. In addition, they can be stored safely for a long period of time. The dipeptide compounds are useful as inhibitors of SARS coronavirus as well as acting as excellent capturing materials of SARS coronavirus.
    Type: Application
    Filed: May 26, 2010
    Publication date: December 2, 2010
    Applicant: ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE
    Inventors: Soo-Hyung LEE, Hyo-Bong Hong, Tao-Wan Kim, Myung-Ae Chung, Sung-Woo Sohn, Seoung-Min Yoo
  • Publication number: 20200179367
    Abstract: In one aspect, a coronavirus is treated by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In another aspect, oxidative stress is reduced in an individual suffering from a coronavirus by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In another aspect, mitochondrial reactive oxygen species (mtROS) are inhibited in an individual suffering from a coronavirus by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In one example, the coronavirus is Covid-19.
    Type: Application
    Filed: February 17, 2020
    Publication date: June 11, 2020
    Inventor: Jonnie R. Williams
  • Patent number: 7981427
    Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (e.g., Quebec and LY138) and human coronavirus strain OC43.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: July 19, 2011
    Assignee: The Royal Veterinary College
    Inventors: John Brownlie, Victoria Jane Chalker, Kerstin Erles
  • Publication number: 20070248616
    Abstract: A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (e.g. Quebec and LY138) and human coronavirus strain OC43. The CRCV spike, polymerase and hemagglutinin/esterase cDNA and protein partial sequences are listed in FIGS. (1) to (4), (13) and (14).
    Type: Application
    Filed: July 1, 2003
    Publication date: October 25, 2007
    Inventors: John Brownlie, Victoria Chalker, Kerstin Erles
  • Publication number: 20060240530
    Abstract: The present invention provides a cDNA of a severe acute respiratory syndrome (SARS) coronavirus, recombinant SARS coronavirus vectors, and SARS coronavirus replicon particles. Also provided are methods of making the compositions of this invention and methods of using the compositions as immunogens and/or vaccines and/or to express heterologous nucleic acids.
    Type: Application
    Filed: January 19, 2006
    Publication date: October 26, 2006
    Inventors: Ralph Baric, Rhonda Roberts, Boyd Yount, Kristopher Curtis
  • Publication number: 20050095582
    Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.
    Type: Application
    Filed: November 3, 2003
    Publication date: May 5, 2005
    Applicants: Diagnostic Hybrids, Inc., Health Research Incorporated
    Inventors: Laura Gillim-Ross, Jill Taylor, David Scholl, David Wentworth, Joseph Jollick
  • Publication number: 20080076115
    Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.
    Type: Application
    Filed: November 3, 2004
    Publication date: March 27, 2008
    Inventors: David R. Scholl, Joseph D. Jollick, Laura Gillim-Ross, Jill Taylor, David E. Wentworth
  • Publication number: 20100273997
    Abstract: Provided is a ribozyme to cleave a coronavirus gene and a therapeutic agent for a coronavirus infectious disease. A common base sequence in coronaviruses such as SARS-CoV and MHV was searched to design a ribozyme including a base sequence complementary thereto. Moreover, a therapeutic agent for a coronavirus infectious disease including such ribozyme was obtained.
    Type: Application
    Filed: August 9, 2006
    Publication date: October 28, 2010
    Inventors: Noboru Fukuda, Takahiro Ueno, Akiko Fukushima, Kazumichi Kuroda
  • Publication number: 20110223659
    Abstract: The invention provides compositions and methods for detecting the presence of SARS-coronavirus, for screening anti-SARS coronavirus agents and vaccines, and for reducing infection with plus-strand RNA viruses such as SARS-coronavirus.
    Type: Application
    Filed: December 7, 2010
    Publication date: September 15, 2011
    Inventors: David R. Scholl, Joseph D. Jollick, Laura Gillim-Ross, Jill Taylor, David E. Wentworth
  • Publication number: 20050002901
    Abstract: The present invention provides methods of treating a coronavirus infection, and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from a coronavirus infection. The present invention further provides methods of reducing the risk that an individual will develop a pathological coronavirus infection, that has clinical sequelae. The present invention further provides methods of reducing the risk that an individual will develop SARS. The present invention further provides methods of treating SARS. The methods generally involve administering a therapeutically effective amount of a Type I or Type III interferon receptor agonist and/or a Type II interferon receptor agonist for the treatment of a coronavirus infection.
    Type: Application
    Filed: March 30, 2004
    Publication date: January 6, 2005
    Inventor: Lawrence Blatt
  • Publication number: 20060123499
    Abstract: The present invention is directed towards the use of the masked palm civet Paguma larvata (“civet”) as an animal model system for SARS, and is based on the novel demonstration of the present invention that civets may be infected with exogenous coronavirus, and that such infection produces SARS-like symptoms in these infected animals. The present invention is directed to a civet model system for the study of the infection, replication, and clinical effects of exogenously introduced human SARS-CoV coronavirus strains, civet SARS-CoV-like coronavirus strains, or variants or derivatives thereof, and to the development of vaccines (or other methods of prevention) or treatment of infection or transmission to other civets or humans of these human SARS-CoV coronavirus strains, civet SARS-CoV-like coronavirus strains, or variants or derivatives thereof.
    Type: Application
    Filed: December 6, 2004
    Publication date: June 8, 2006
    Inventors: Donglai Wu, Xiangang Kong, Qingwen Meng, Yonggang Liu, Yuntao Guan, Xunnan Yin, Mouping Wang, Changwen Li, Ming Liao, Chao-an Xin, Jinding Chen, Changchun Tu, Hua Xuan, Yedong Yu
Narrow Results

Filter by US Classification